Biography Dr. Schumacher is Professor and Vice Chair of Pain Medicine in the Department of Anesthesia and Perioperative Care, University of California, San Francisco. He has a clinical, research and educational focus on pain medicine with an emphasis on the development of evidence – based pain care into general clinical practice that utilize non-addictive modalities to improve both the quality and safety of analgesic care. Dr. Schumacher is also the Director of the UCSF Pain and Addiction Research Center (PARC) and served on the National Academies of Science Engineering and Medicine Committee, co-authoring the report on “Pain Management and the Opioid Epidemic.” Scientifically, following his collaboration in the cloning of the Capsaicin Receptor (TRPV1), he has led a laboratory dedicated to non-addictive strategies to block the transition from acute to chronic pain through transcriptional blockade. His current NIH-funded research includes: Study of painful Chemotherapy-Induced Peripheral Neuropathy (CIPN) with the aim to develop novel therapeutics and studying Neuro-immune Mechanisms of Analgesia of the Minor Cannabinoids such as CBD as well as its developmental effects on sensory neurons. Throughout his career, he has sought ways to communicate the science and practice of pain medicine including previously directing an NIH Center of Excellence in Pain Education at UCSF. Role Faculty Location UCSF at Parnassus Category Clinical Specialties Pain Medicine Publications Peripheral Neuroinflammation and Pain: How Acute Pain Becomes Chronic. Schumacher MA Chemotherapy for pain: reversing inflammatory and neuropathic pain with the anticancer agent mithramycin A. Xu Z, Lee MC, Sheehan K, Fujii K, Rabl K, Rader G, Varney S, Sharma M, Eilers H, Kober K, Miaskowski C, Levine JD, Schumacher MA N-Oleoyl dopamine induces IL-10 via central nervous system TRPV1 and improves endotoxemia and sepsis outcomes. Joffre J, Wong E, Lawton S, Lloyd E, Nguyen N, Xu F, Sempio C, Kobzik L, Zlatanova I, Schumacher M, Klawitter J, Su H, Rabl K, Wilhelmsen K, Yeh CC, Hellman J Long-Term Trends in Postoperative Opioid Prescribing, 1994 to 2014. Chen CL, Jeffery MM, Krebs EE, Thiels CA, Schumacher MA, Schwartz AJ, Thombley R, Finlayson E, Rodriguez-Monguio R, Ward D, Dudley RA Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pa Kober KM, Lee MC, Olshen A, Conley YP, Sirota M, Keiser M, Hammer MJ, Abrams G, Schumacher M, Levine JD, Miaskowski C Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors. Miaskowski C, Topp K, Conley YP, Paul SM, Melisko M, Schumacher M, Chesney M, Abrams G, Levine JD, Kober KM Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors. Petrovchich I, Kober KM, Wagner L, Paul SM, Abrams G, Chesney MA, Topp K, Smoot B, Schumacher M, Conley YP, Hammer M, Levine JD, Miaskowski C Transcription factor Sp4 is required for hyperalgesic state persistence. Sheehan K, Lee J, Chong J, Zavala K, Sharma M, Philipsen S, Maruyama T, Xu Z, Guan Z, Eilers H, Kawamata T, Schumacher M Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors. Wong ML, Cooper BA, Paul SM, Abrams G, Topp K, Kober KM, Chesney MA, Mazor M, Schumacher MA, Conley YP, Levine JD, Miaskowski C Pain Management and Opioid Regulation: Continuing Public Health Challenges. Bonnie RJ, Schumacher MA, Clark JD, Kesselheim AS Signaling pathways and gene co-expression modules associated with cytoskeleton and axon morphology in breast cancer survivors with chronic paclitaxel-induced peripheral neuropathy. Kober KM, Schumacher M, Conley YP, Topp K, Mazor M, Hammer MJ, Paul SM, Levine JD, Miaskowski C Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Kober KM, Olshen A, Conley YP, Schumacher M, Topp K, Smoot B, Mazor M, Chesney M, Hammer M, Paul SM, Levine JD, Miaskowski C Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. Kober KM, Mazor M, Abrams G, Olshen A, Conley YP, Hammer M, Schumacher M, Chesney M, Smoot B, Mastick J, Paul SM, Levine JD, Miaskowski C Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors. Miaskowski C, Paul SM, Mastick J, Abrams G, Topp K, Smoot B, Kober KM, Chesney M, Mazor M, Mausisa G, Schumacher M, Conley YP, Sabes JH, Cheung S, Wallhagen M, Levine JD Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life. Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, Kober KM, Schumacher M, Conley YP, Topp K, Smoot B, Mausisa G, Mazor M, Wallhagen M, Levine JD Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy. Miaskowski C, Paul SM, Mastick J, Schumacher M, Conley YP, Smoot B, Abrams G, Kober KM, Cheung S, Henderson-Sabes J, Chesney M, Mazor M, Wallhagen M, Levine JD America's Opioid Epidemic: Supply and Demand Considerations. Clark DJ, Schumacher MA N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1. Lawton SK, Xu F, Tran A, Wong E, Prakash A, Schumacher M, Hellman J, Wilhelmsen K (431) Characteristics of chemotherapy induced neuropathy (CIN) in cancer survivors who received taxol. K. Kober, J. Mastick, S. Paul, K. Topp, B. Smoot, G. Abrams, L. Chen, Y. Conley, M. Chesney, K. Bolla, G. Mausisa, M. Azor, M. Wong, M. Schumacher, J. Levine, C. Miaskowski Chemotherapy-Induced Neuropathy in Cancer Survivors. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, Chen LM, Kober KM, Conley YP, Chesney M, Bolla K, Mausisa G, Mazor M, Wong M, Schumacher M, Levine JD Contemporary views on inflammatory pain mechanisms: TRPing over innate and microglial pathways. Guan Z, Hellman J, Schumacher M The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons. Zavala K, Lee J, Chong J, Sharma M, Eilers H, Schumacher MA Back pain and the mineralocorticoid receptor: is there a connection? Schumacher MA Pain Management for the Obese Sleep Apnea Patient. Mark A. Schumacher Transcription factors Sp1 and Sp4 regulate TRPV1 gene expression in rat sensory neurons. Chu C, Zavala K, Fahimi A, Lee J, Xue Q, Eilers H, Schumacher MA Cutaneous nerve transection for the management of intractable upper extremity pain caused by invasive squamous cell carcinoma. Turnbull JH, Gebauer SL, Miller BL, Barbaro NM, Blanc PD, Schumacher MA Pungent general anesthetics activate transient receptor potential-A1 to produce hyperalgesia and neurogenic bronchoconstriction. Eilers H, Cattaruzza F, Nassini R, Materazzi S, Andre E, Chu C, Cottrell GS, Schumacher M, Geppetti P, Bunnett NW TRPV1 splice variants: structure and function. Schumacher MA, Eilers H Transient receptor potential channels in pain and inflammation: therapeutic opportunities. Schumacher MA The rat vanilloid receptor splice variant VR.5'sv blocks TRPV1 activation. Eilers H, Lee SY, Hau CW, Logvinova A, Schumacher MA Determinants of the anesthetic sensitivity of two-pore domain acid-sensitive potassium channels: molecular cloning of an anesthetic-activated potassium channel from Lymnaea stagnalis. Andres-Enguix I, Caley A, Yustos R, Schumacher MA, Spanu PD, Dickinson R, Maze M, Franks NP Transcription of rat TRPV1 utilizes a dual promoter system that is positively regulated by nerve growth factor. Xue Q, Jong B, Chen T, Schumacher MA Isolation of an mRNA binding protein homologue that is expressed in nociceptors. Eilers H, Trilk SL, Lee SY, Xue Q, Jong BE, Moff I, Levine JD, Schumacher MA Opioid-induced respiratory depression: are 5-HT4a receptor agonists the cure? Eilers H, Schumacher MA The genomic organization of the gene encoding the vanilloid receptor: evidence for multiple splice variants. Xue Q, Yu Y, Trilk SL, Jong BE, Schumacher MA The reversal of fentanyl-induced tolerance by administration of "small-dose" ketamine. Eilers H, Philip LA, Bickler PE, McKay WR, Schumacher MA Room B, 10/16/2000 2: 00 PM - 4: 00 PM (PS) The Capsaicin Receptor Variant, Stretch-inactivated Channel, Is Expressed in Small-Diameter Sensory Neurons. Mark A. Schumacher, Beverly E. Jong, Sharon L. Frey, Norman F. Capra, Jon D. Levine The stretch-inactivated channel, a vanilloid receptor variant, is expressed in small-diameter sensory neurons in the rat. Schumacher MA, Jong BE, Frey SL, Sudanagunta SP, Capra NF, Levine JD Molecular cloning of an N-terminal splice variant of the capsaicin receptor. Loss of N-terminal domain suggests functional divergence among capsaicin receptor subtypes. Schumacher MA, Moff I, Sudanagunta SP, Levine JD ISOLATION OF NERVE GROWTH FACTOR (NGF) REGULATED GENES IN PRIMARY AFFERENT NEURONS. Mark A. Schumacher, Irene Moff, Jon D. Levine The capsaicin receptor: a heat-activated ion channel in the pain pathway. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D ATP receptors in sickness, pain and death. Brake A, Schumacher M, Julius D
